RT Journal Article
SR Electronic
T1 International BEAT-PCD Consensus Statement for Infection Prevention and Control for Primary Ciliary Dyskinesia in collaboration with ERN-LUNG PCD Core NETWORK and patient representatives
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00301-2021
DO 10.1183/23120541.00301-2021
A1 June K. Marthin
A1 Jane S. Lucas
A1 Mieke Boon
A1 Carmen Casaulta
A1 Suzanne Crowley
A1 Damien M.S. Destouches
A1 Ernst Eber
A1 Amparo Escribano
A1 Eric Haarman
A1 Claire Hogg
A1 Bernard Maitre
A1 Gemma Marsh
A1 Vendula Martinu
A1 Antonio Moreno-Galdó
A1 Huda Mussaffi
A1 Heymut Omran
A1 Petr Pohunek
A1 Bernhard Rindlisbacher
A1 Phil Robinson
A1 Deborah Snijders
A1 Woolf T. Walker
A1 Panayiotis Yiallouros
A1 Helle Krogh Johansen
A1 Kim G. Nielsen
YR 2021
UL http://openres.ersjournals.com/content/early/2021/05/21/23120541.00301-2021.abstract
AB Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD Network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative was now taken towards creating such consensus statement.Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment, and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process.Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current COVID-19 pandemic.Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Lucas has nothing to disclose.